The launch of Wegovy by Novo Nordisk in the United States as the first-ever oral GLP-1 medication for treating obesity, as well as the advancement of orforglipron by Eli Lilly, will affect competition, as companies strive to develop more convenient and better-tolerated medications that can provide good payer value
Based upon these results, disruption of the BBB and ischemia-induced inflammation could be ameliorated by Ex-4 in an astrocyte-dependent way
And the warning signs that your levothyroxine dose needs adjusting
Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus
Obesity has been identified as the most important risk factor in the development and progression of type 2 diabetes [6], and also as a risk factor for decreased estimated glomerular filtration rate (eGFR) and increased albuminuria (markers of kidney disease) [7, 8]
European Journal of Applied Physiology, 99(2), 193199